3 CRISPR-Cas Genome Editing: Emerging Trends and Therapeutic Applications

Mrs. Komal Goyal*
Research Scholar, Mangalayatan University, Uttar Pradesh.
*Corresponding Author: komal.goyal251190@gmail.com

Abstract

Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) have transformed molecular biotechnology by enabling programmable modification and regulation of genetic information. Originally characterized as an adaptive immune mechanism in bacteria and archaea, CRISPR systems have been adapted as versatile tools for genome, epigenome and transcriptome engineering. The widely used CRISPR-Cas9 platform relies on guide-RNA-directed recognition of a target sequence adjacent to a protospacer-adjacent motif (PAM), followed by DNA cleavage and cellular repair. Newer approaches—including cytosine and adenine base editing, prime editing, CRISPR interference, CRISPR activation and RNA-targeting Cas enzymes—extend the technology beyond conventional double-strand DNA breaks. Therapeutic development is progressing in inherited blood disorders, cancer immunotherapy, metabolic disease, inherited retinal disease and infectious-disease research. The approval of exagamglogene autotemcel (Casgevy) for eligible patients with sickle cell disease and transfusion-dependent β-thalassemia represents a major clinical milestone. Nevertheless, off-target activity, unintended on-target genomic changes, delivery barriers, immune responses, manufacturing complexity, cost and ethical governance remain important challenges. This chapter reviews the molecular basis of CRISPR-Cas editing, emerging technological platforms, delivery strategies, therapeutic applications, safety considerations and future directions. It generally emphasizes the distinction between approved therapies and investigational approaches and discusses the importance of rigorous genomic assessment, long-term follow-up and equitable access in the responsible translation of genome-editing technologies.

Keywords: Crispr-Cas9, Genome Editing, Base Editing, Prime Editing, Gene Therapy, Precision Medicine, Molecular Biotechnology, Therapeutic Genome Engineering, Gene Regulation, Rna Targeting.

Introduction

The ability to alter genetic information at defined genomic locations has become a central objective of modern biotechnology. Genome editing provides a means to investigate gene function, construct disease models, engineer cells and potentially correct the molecular causes of inherited disorders. Earlier platforms, including zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), established the feasibility of programmable DNA cleavage, but their protein-engineering requirements could make target redesign laborious. CRISPR systems changed this landscape by using a guide RNA to direct a nuclease to a complementary nucleic-acid sequence.

CRISPR is an acronym for clustered regularly interspaced short palindromic repeats. In bacteria and archaea, CRISPR arrays and associated proteins provide adaptive defence against invading genetic elements such as bacteriophages and plasmids. During adaptation, fragments of foreign DNA may be incorporated as spacers into a CRISPR locus. During subsequent exposure, CRISPR RNAs guide Cas effector proteins to matching nucleic acids, enabling their recognition and destruction. Researchers repurposed this biological mechanism as a programmable platform for targeted genome engineering (Jinek et al., 2012; Doudna & Charpentier, 2014).

The CRISPR toolbox now extends well beyond Cas9-mediated DNA cleavage. Base editors can convert selected nucleotide pairs without generating a conventional double-strand break, prime editors can write a range of small sequence changes using a reverse-transcription template, and catalytically inactive Cas proteins can regulate transcription or epigenetic states. RNA-targeting systems, particularly Cas13, provide additional opportunities for transient manipulation and nucleic-acid detection. These developments are broadening the scope of basic research and therapeutic biotechnology (Villiger et al., 2024; Pacesa et al., 2024).

Historical Development of CRISPR-Cas Technology

Unusual repeated DNA sequences were reported in Escherichia coli in 1987. Their function remained uncertain until related repeat-spacer arrays were recognized in diverse prokaryotes and the term CRISPR was introduced. In 2007, experimental work demonstrated that CRISPR provides acquired resistance to bacteriophages in bacteria. The molecular components and the role of CRISPR-associated proteins were subsequently elucidated. In 2012, Jinek and colleagues demonstrated that Cas9 could be programmed by a dual-RNA system to cleave a selected DNA target in vitro. In 2013, independent groups demonstrated genome editing in mammalian cells, rapidly establishing CRISPR-Cas9 as a major research tool (Barrangou et al., 2007; Cong et al., 2013; Mali et al., 2013).

ISBN: 978-93-49468-07-8

Subsequent milestones included the development of CRISPR interference for gene repression, base editing, prime editing and RNA-targeting Cas enzymes. Clinical translation followed, with the first regulatory approval of a CRISPR-based medicine in 2023. Regulatory indications have since evolved; as of November 2026, the US Food and Drug Administration lists Casgevy for eligible patients aged two years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia. Regulatory labels differ by jurisdiction and should be checked at the time of publication (FDA, 2026).

Molecular Components of the CRISPR-Cas9 System

- **Cas9 Endonuclease**

Cas9 is an RNA-guided DNA endonuclease. The protein contains recognition and nuclease regions that coordinate target binding and DNA cleavage. The HNH domain cleaves the DNA strand complementary to the guide RNA, while the RuvC domain cleaves the non-complementary strand. Catalytically modified Cas9 variants include nickases, which cut one DNA strand, and dead Cas9 (dCas9), in which nuclease activity is disabled but sequence-specific DNA binding is retained.

- **Guide RNA**

In the commonly used Streptococcus pyogenes Cas9 system, the natural crRNA and tracrRNA can be combined into a single-guide RNA (sgRNA). The guide region, often approximately 20 nucleotides in length, determines target recognition through base pairing with the DNA. The scaffold region supports interaction with Cas9. Guide design must account for target sequence, PAM availability, genomic context, sequence uniqueness and the possibility of off-target binding.

- **Protospacer-Adjacent Motif**

The protospacer-adjacent motif (PAM) is a short DNA sequence adjacent to the target site and is required for recognition by many Cas nucleases. SpCas9 commonly recognizes a 5′-NGG-3′ PAM, where N can be any nucleotide. Other Cas proteins and engineered variants recognize different PAMs, expanding the range of accessible genomic sites.

- **Target DNA and Repair Template**

The target DNA is the genomic sequence selected for modification. For conventional Cas9 editing, a donor DNA template may be supplied when a defined insertion or correction is intended through homology-directed repair. The availability and design of the donor template, together with the cell's repair state, influence the outcome.

Mechanism of CRISPR-Cas9 Genome Editing

The process begins when sgRNA associates with Cas9 to form a ribonucleoprotein complex. The complex scans DNA for a compatible PAM. PAM

ISBN: 978-93-49468-07-8

recognition promotes local DNA unwinding and permits guide-RNA pairing with the complementary target strand. If sufficient complementarity is achieved, conformational changes activate the HNH and RuvC nuclease domains, which cleave opposite DNA strands and generate a double-strand break. The break is then processed by endogenous DNA-repair pathways.

- **Non-homologous End Joining**

Non-homologous end joining (NHEJ) reconnects broken DNA ends without requiring a long homologous donor template. Repair can be efficient but may introduce small insertions or deletions (indels). If these changes disrupt a coding sequence or regulatory element, they may reduce or abolish gene function. NHEJ and related end-joining pathways are therefore frequently used for gene disruption, although outcomes can be heterogeneous.

- **Homology-Directed Repair**

Homology-directed repair (HDR) uses a homologous DNA sequence as a template. When a donor template is provided, HDR can introduce a defined sequence change, insertion or correction. HDR efficiency varies with cell type, cell-cycle stage, donor design and delivery conditions. It is often less active in quiescent cells than in rapidly dividing cells, limiting its utility in some therapeutic settings.




Figure 1: Schematic representation of CRISPR-Cas9 target recognition, DNA cleavage and repair outcomes through NHEJ and HDR. The SpCas9 PAM is commonly NGG. The diagram is a conceptual illustration and is not drawn to molecular scale.

ISBN: 978-93-49468-07-8

Emerging Trends in CRISPR Genome Editing

- **Base Editing**

Base editing enables selected nucleotide conversions without generating a conventional double-strand DNA break. Cytosine base editors generally mediate C•G-to-T•A conversion, while adenine base editors mediate A•T-to-G•C conversion. These systems commonly combine a catalytically impaired Cas protein or nickase with a deaminase enzyme. Base editors may be useful for pathogenic point mutations that fall within an accessible editing window. Limitations include bystander editing of nearby bases, sequence-context dependence and potential DNA or RNA off-target activity (Komor et al., 2016; Gaudelli et al., 2017).

- **Prime Editing**

Prime editing, introduced by Anzalone and colleagues (2019), combines a Cas9 nickase with a reverse transcriptase and a prime-editing guide RNA (pegRNA). The pegRNA contains a targeting sequence and an extension encoding a primer-binding site and reverse-transcription template. Following target recognition and nicking, the cellular DNA end can prime reverse transcription of the programmed sequence. Prime editing can mediate selected substitutions and small insertions or deletions without a conventional double-strand break or a separate donor DNA molecule. Editing efficiency and product purity vary by target, cell type, editor configuration and delivery method.

- **CRISPR Interference and Activation**

CRISPR interference (CRISPRi) uses dCas9, often fused to a transcriptional repressor or directed to a promoter or gene body, to reduce transcription. CRISPR activation (CRISPRa) uses dCas9 fused to transcriptional activation domains to increase gene expression. Because these systems generally do not alter the DNA sequence, they are useful for functional genomics, pathway analysis and reversible or tunable gene regulation. Their effects depend on guide placement, chromatin state and the regulatory domains employed (Qi et al., 2013).

- **RNA-targeting CRISPR Systems**

Cas13 family proteins use guide RNAs to recognize RNA rather than DNA. RNA-targeting systems can support transcript detection, transient knockdown and experimental RNA manipulation without permanently changing genomic DNA. CRISPR-based diagnostic platforms have also been developed using collateral-cleavage activity of selected Cas enzymes, enabling sequence-specific detection of nucleic acids. Diagnostic performance depends on assay design, sample preparation, controls and validation in the intended clinical setting (Abudayyeh et al., 2016; Gootenberg et al., 2017).

ISBN: 978-93-49468-07-8

- **High-fidelity and Expanded-PAM Cas Variants**

Engineered Cas variants have been developed to improve specificity, alter PAM recognition or enable access to additional genomic sites. High-fidelity variants aim to reduce cleavage at partially matched sequences. Expanded-PAM variants can increase targetability, although each variant must be evaluated for activity and specificity in the relevant cell type and genomic context.

- **Artificial Intelligence and Computational Design**

Machine-learning approaches are increasingly used to rank guide RNAs, predict editing efficiency, identify potential off-target sites and interpret large genomic datasets. AI can support candidate selection and experimental prioritization, but computational predictions do not replace empirical testing. Prediction quality depends on the training data, assay conditions and representation of relevant cell types and genomic contexts (Villiger et al., 2024).

- **Epigenome and Chromatin Editing**

Catalytically inactive Cas proteins can be fused to epigenetic effectors to alter DNA methylation, histone modifications or chromatin accessibility at selected loci. Such approaches may provide a means to modulate gene expression without changing the underlying DNA sequence. Their durability, reversibility, specificity and consequences for neighbouring genes remain active areas of research.

Table 1: Comparison of Major CRISPR-based Genome and Gene-Regulation Technologies

Technology	Core Components	Typical Outcome	Conventional DSB?	Representative Use
CRISPR-Cas9 nuclease	Cas9 + sgRNA	Indels; gene disruption; HDR-mediated edits	Yes	Gene knockout or targeted insertion
Cytosine base editing	Cas nickase/dCas + cytidine deaminase	C•G to T•A conversion	No	Selected point-mutation correction
Adenine base editing	Cas nickase/dCas + adenine deaminase	A•T to G•C conversion	No	Selected point-mutation correction
Prime editing	Cas9 nickase + reverse transcriptase + pegRNA	Selected substitutions and small insertions/deletions	No conventional DSB	Precision sequence rewriting
CRISPRi / CRISPRa	dCas9 + repressor/activator	Gene-expression reduction/increase	No	Functional genomics and gene regulation
Cas13 RNA targeting	Cas13 + guide RNA	RNA recognition or modulation	No DNA cleavage	RNA research and diagnostics

ISBN: 978-93-49468-07-8

Therapeutic Applications

- **Sickle Cell Disease**

Sickle cell disease is caused by pathogenic variants in HBB that lead to production of haemoglobin S. Under deoxygenated conditions, haemoglobinS can polymerize, deforming red blood cells and contributing to haemolysis, vaso-occlusion, pain and progressive organ injury. One therapeutic strategy edits the erythroid-specific enhancer of BCL11A in a patient's haematopoietic stem and progenitor cells. BCL11A normally represses fetal haemoglobin after birth; reducing its expression in the erythroid lineage can increase fetal haemoglobin, which inhibits haemoglobin S polymerization. Exagamglogene autotemcel (exa-cel; Casgevy) is an autologous, ex vivo CRISPR-edited cell therapy based on this strategy. It received initial US approval in 2023 for eligible patients with sickle cell disease and was subsequently approved for transfusion-dependent β-thalassemia in 2024. FDA product information updated in July 2026 lists indications for patients aged two years and older; age and eligibility criteria should always be checked against the current local label (Frangoul et al., 2021; FDA, 2026).

- **Transfusion-Dependent Beta-Thalassemia**

Beta-thalassemia results from reduced or absent production of beta-globin chains, leading to ineffective erythropoiesis and anaemia. In severe transfusion-dependent disease, repeated transfusions may be required and can cause iron overload. Exa-cel edits the BCL11A erythroid enhancer in autologous CD34-positive cells, increasing fetal haemoglobin after reinfusion. Clinical evidence supports the therapeutic potential of this approach, but treatment involves stem-cell collection, myeloablative conditioning, specialized manufacturing and prolonged clinical monitoring.

- **Cancer Immunotherapy**

CRISPR editing is being investigated to engineer T cells and other immune-cell populations for cancer treatment. Editing may remove inhibitory receptors, alter signalling pathways, improve persistence or support the development of allogeneic cell products. CRISPR screens can also identify genes that influence tumour growth, immune evasion and resistance to therapy. Most applications remain investigational; the clinical value depends on tumour type, target selection, cell manufacturing, safety and durable anti-tumour activity.

- **Inherited Retinal and Other Monogenic Disorders**

The eye is an attractive target for some in vivo genome-editing strategies because it is anatomically accessible and certain ocular compartments may be treated locally. Investigational approaches have explored editing disease-associated variants in inherited retinal disorders. Other monogenic conditions—including

ISBN: 978-93-49468-07-8

selected forms of muscular dystrophy, cystic fibrosis, haemophilia and metabolic disease—are being studied using nuclease editing, base editing or prime editing. These programmes differ in maturity and should not be described as established treatments unless a therapy has received relevant regulatory approval.

- **Metabolic and Cardiovascular Disorders**

The liver is a major target for in vivo genome editing because of its central role in protein synthesis and metabolism and the ability of lipid nanoparticles to deliver nucleic-acid cargo to hepatocytes. Investigational targets include genes involved in lipid metabolism, such as PCSK9, and proteins associated with inherited metabolic disorders. The objective may be to reduce production of a harmful protein or restore a functional pathway. Long-term monitoring is important because edits in long-lived cells may persist.

- **Infectious Diseases and Diagnostics**

CRISPR systems are being explored for detection of viral, bacterial and other pathogen-associated nucleic acids, as well as for experimental targeting of pathogen genomes or transcripts. Cas12- and Cas13-based assays have supported the development of rapid molecular detection platforms. Therapeutic applications against persistent viruses face challenges such as delivery to all infected reservoirs, viral sequence diversity and the possibility of escape mutations. CRISPR diagnostics require independent analytical and clinical validation before routine use.

- **Neurological Disorders**

Potential applications in neurological disease include disorders caused by single-gene variants, such as selected inherited epilepsies and neurodegenerative conditions. Delivery across the blood-brain barrier, distribution across relevant neuronal populations, cell-type specificity and the consequences of editing long-lived post-mitotic cells are substantial challenges. Current work is largely preclinical or early translational.

Table 2: Selected Therapeutic Areas and the Status of CRISPR Approaches

Disease/area	Target or Strategy	Therapeutic Rationale	Status Summary
Sickle cell disease	BCL11A erythroid enhancer editing	Increase fetal haemoglobin	Casgevy approved for eligible patients
Transfusion-dependent β-thalassemia	BCL11A erythroid enhancer editing	Increase fetal haemoglobin	Casgevy approved for eligible patients
Cancer	CRISPR-engineered immune cells; target discovery	Improve immune-cell function and identify vulnerabilities	Investigational

ISBN: 978-93-49468-07-8

Transthyretin amyloidosis	TTR gene editing	Reduce pathogenic transthyretin production	Investigational clinical development
Hereditary angioedema	KLKB1 pathway editing	Reduce kallikrein pathway activity	Investigational clinical development
Inherited retinal disease	Disease-specific ocular targets	Address pathogenic variants in retinal cells	Investigational
Dyslipidaemia	PCSK9 pathway editing	Reduce LDL-cholesterol through altered PCSK9 activity	Investigational

Ex Vivo and in Vivo Therapeutic Strategies

Ex vivo editing involves collecting cells from a patient, modifying them outside the body, evaluating the resulting cell product and administering the cells back to the patient. This approach allows some quality-control testing before infusion and is particularly suited to haematopoietic stem cells and immune cells. It may nevertheless require conditioning regimens, specialized facilities and individualized manufacturing.

In vivo editing involves delivering genome-editing components directly to tissues in the body. Delivery vehicles may include lipid nanoparticles, viral vectors or other engineered carriers. In vivo strategies may be useful for organs such as the liver and eye, but require sufficient delivery to the correct cell population while limiting exposure to non-target tissues. The distinction between ex vivo and in vivo approaches is illustrated in Figure 3.




Figure 2: Conceptual Comparison of Ex Vivo Cell Collection, Editing and Reinfusion with in Vivo Delivery and Editing within Target Tissues

ISBN: 978-93-49468-07-8

Delivery Systems for CRISPR Therapeutics

Delivery is a major determinant of therapeutic success. The editing machinery must reach the relevant cell type, enter the appropriate intracellular compartment and remain active long enough to achieve the intended edit. Delivery strategies are selected according to cargo size, target tissue, desired duration of expression, immune considerations and manufacturing requirements.

- **Viral Vectors**

Adeno-associated viral vectors can deliver genetic material to selected tissues and have been widely investigated in gene therapy. Their limitations include packaging capacity, pre-existing or induced immune responses, potential difficulty with redosing and concerns associated with prolonged expression of an editing nuclease. Split-vector or compact-editor approaches may address some constraints but add design complexity.

- **Lipid Nanoparticles**

Lipid nanoparticles can encapsulate RNA or other nucleic-acid cargo and support transient delivery. They have been important in in vivo genome-editing research, particularly for liver-directed applications. Formulation, biodistribution, endosomal escape and tissue specificity remain central optimization challenges.

- **Electroporation and RNP Delivery**

Electroporation transiently increases cell-membrane permeability and is widely used for ex vivo delivery of Cas9 protein, guide RNA or nucleic acids. Delivery of a preassembled Cas9-guide RNA ribonucleoprotein can produce rapid, transient exposure to the editing machinery. These approaches are valuable for cell products but are not directly applicable to all tissues in vivo.

Table 3: Comparison of Commonly used CRISPR Delivery Systems

Delivery System	Cargo/delivery Principle	Advantages	Limitations and Considerations
AAV vectors	Viral vector expressing editor and/or guide RNA	Efficient transduction in selected tissues; established vector platform	Limited packaging capacity; immune responses; prolonged expression
Lipid nanoparticles	Encapsulated mRNA, guide RNA or other nucleic acids	Non-viral; transient expression possible; scalable formulation	Biodistribution and tissue targeting; endosomal escape; repeat dosing
Electroporation	Electrical pulses introduce RNP or nucleic acids into cells	Useful for ex vivo cell engineering; transient exposure	Can reduce cell viability; requires cell handling and equipment
RNP delivery	Preassembled Cas protein-guide RNA complex	Rapid activity and limited duration of nuclease exposure	Cell-type-dependent uptake; formulation and delivery optimization

ISBN: 978-93-49468-07-8

Advantages and Potential Benefits

CRISPR technologies offer programmability, flexibility and relative ease of redesign because target recognition is largely determined by guide RNA sequence. Multiple loci can be investigated in parallel, supporting high-throughput functional screens. The toolbox includes DNA cleavage, nucleotide conversion, sequence rewriting, RNA targeting and transcriptional or epigenetic regulation. These capabilities are useful in disease modelling, target validation, cell engineering and the development of precision therapies. The clinical success of exa-cel demonstrates that genome editing can progress from laboratory research to an approved therapeutic product when supported by robust manufacturing, clinical evidence and regulatory evaluation.

Safety, Limitations and Challenges

- **Off-target Editing**

Off-target editing occurs when the guide RNA-Cas complex modifies unintended genomic sites. The risk depends on guide sequence, nuclease variant, chromatin context, dose and exposure time. Computational prediction, biochemical assays, unbiased genome-wide methods and targeted sequencing can be combined to assess specificity. No single assay captures every possible unintended event.

- **Unintended on-Target Outcomes**

Even at the intended target, double-strand breaks can lead to large deletions, inversions, translocations or complex repair outcomes in addition to small indels. These events may be missed by assays that only quantify short-range sequence changes. Comprehensive characterization of edited cells is therefore essential, particularly for therapeutic products.

- **Immune Responses and Toxicity**

Cas proteins are derived from microorganisms and may be recognized by the human immune system. Delivery vectors and nanoparticle components may also trigger immune responses. Conditioning regimens used in some ex vivo therapies can produce significant toxicities. Safety evaluation must consider the editor, delivery vehicle, cell product and entire treatment pathway.

- **Delivery and Tissue Specificity**

Efficient delivery to the relevant cell population remains difficult in many organs. Off-tissue exposure can increase risk, while insufficient delivery can reduce efficacy. The need for transient versus durable expression differs by application, and the optimal delivery strategy must be selected for each target tissue.

- **Manufacturing, Cost and Access**

Personalized cell products require specialized facilities, validated manufacturing processes, release testing and long-term follow-up. These

ISBN: 978-93-49468-07-8

requirements can result in high treatment costs and limited availability. Equitable access, affordability and the development of scalable manufacturing methods are important translational priorities.

- **Ethical and Governance Considerations**

Somatic genome editing affects non-reproductive cells and is not ordinarily transmitted to future generations. Germline editing of embryos or reproductive cells may create heritable changes and raises profound ethical, social and legal concerns. International guidance emphasizes responsible oversight, transparency, public engagement, informed consent and robust governance. Clinical development should distinguish treatment of serious disease from enhancement applications and should avoid claims that exceed the available evidence.

Regulatory and Clinical Translation Considerations

Clinical genome editing requires evidence of product identity, purity, potency, safety and efficacy. Regulators evaluate manufacturing consistency, off-target risk, unintended genomic changes, biodistribution, immune responses and long-term outcomes. For autologous cell therapies, chain of identity and chain of custody are critical because each product is manufactured for an individual patient. Follow-up may be required to monitor durability and delayed adverse events.

Casgevy illustrates the complexity of clinical translation. The product is manufactured from a patient's own CD34-positive haematopoietic stem and progenitor cells. The cells are edited ex vivo at the erythroid-specific BCL11A enhancer and administered following myeloablative conditioning. Its approval should not be interpreted as proof that all CRISPR approaches are safe or effective; each product and indication requires its own evidence and regulatory review. The FDA's current product information should be consulted for the latest age range, indication and warnings.

Future Perspectives

- **More Precise Editing Platforms**

Further optimization of base editors, prime editors and high-fidelity nucleases may improve editing accuracy and broaden the range of correctable variants. The goal is not simply higher editing percentage, but a predictable product profile with minimal unintended changes and demonstrable functional benefit.

- **Tissue-Specific Delivery**

Advances in lipid nanoparticles, engineered viral vectors, ligand-directed carriers and other delivery systems may improve access to disease-relevant cells. Delivery strategies that limit exposure outside the target tissue could improve the therapeutic index.

ISBN: 978-93-49468-07-8

- **AI-Guided Design and Predictive Assessment**

Machine learning may assist guide selection, editor engineering, off-target prediction and analysis of sequencing data. Greater access to well-annotated datasets and standardized experimental benchmarks will be necessary to make these predictions reliable across different biological contexts.

- **Personalized and Mutation-Specific Medicine**

As genomic diagnosis becomes more accessible, genome-editing strategies may increasingly be tailored to individual pathogenic variants. Personalized approaches will require careful assessment of whether the intended edit is technically feasible, biologically meaningful and clinically justified.

- **Responsible Translation and Global Access**

The future of CRISPR therapeutics will depend on more than molecular innovation. Manufacturing capacity, affordability, regulatory harmonization, long-term surveillance and equitable access will influence whether these technologies produce broad public-health benefits. Responsible translation requires ongoing dialogue among scientists, clinicians, patients, regulators and society.




Figure 3: Selected Therapeutic and Translational Areas in which CRISPR-based Technologies are being Investigated. The Examples Include Approved and Investigational Applications; they do not imply that each Application is an Established Treatment

Conclusion

CRISPR-Cas genome editing has become a foundational technology in modern biotechnology, enabling programmable modification and regulation of genetic information. The field has progressed from Cas9-mediated DNA cleavage to a diverse set of platforms that include base editing, prime editing, RNA targeting, transcriptional regulation and epigenome editing. These approaches are expanding research opportunities and creating new therapeutic possibilities in inherited blood disorders, cancer, metabolic disease, retinal disorders and infectious-disease diagnostics.

ISBN: 978-93-49468-07-8

The approval of exagamglogene autotemcel for eligible patients with sickle cell disease and transfusion-dependent β-thalassemia demonstrates the clinical potential of CRISPR-based therapy. At the same time, the technology's broader use depends on solving challenges related to off-target activity, unintended on-target changes, delivery, immune responses, manufacturing complexity, cost and ethical governance. Continued collaboration among molecular biologists, clinicians, bioinformaticians, engineers and regulatory scientists will be essential. With careful evaluation and responsible oversight, CRISPR-based technologies may contribute substantially to the future of precision medicine and biotechnology.

Table 4: Key Challenges and Possible Strategies to Improve Clinical Translation

Challenge	Potential Consequence	Research or Translational Response
Off-target editing	Unintended genomic modification	Improved guide design; high-fidelity editors; genome-wide and targeted assessment
Large or complex on-target changes	Structural genomic alterations	Long-read sequencing and orthogonal genomic assays
Inefficient delivery	Low editing in target cells or off-tissue exposure	Tissue-directed vectors, optimized LNPs and transient RNP delivery
Immune recognition	Inflammation or reduced editor activity	Immune monitoring; editor and vector engineering; careful patient selection
Manufacturing complexity	Variable product quality and limited scale	Standardized processes, validated release assays and automation
High cost and limited access	Unequal availability of therapy	Scalable manufacturing, health-economic evaluation and access programmes
Ethical and governance concerns	Loss of public trust or misuse	Transparent oversight, informed consent and public engagement

References

1. Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., et al. (2017). RNA targeting with CRISPR-Cas13. Nature, 550, 280–284. https://doi.org/10.1038/nature24049
2. Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576, 149–157. https://doi.org/10.1038/s41586-019-1711-4

ISBN: 978-93-49468-07-8

3. Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science, 315(5819), 1709–1712. https://doi.org/10.1126/science.1138140

4. Chavez, M., Chen, X., Finn, P. B., & Qi, L. S. (2023). Advances in CRISPR therapeutics. Nature Reviews Nephrology, 19, 9–22. https://doi.org/10.1038/s41581-022-00612-7

5. Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819–823. https://doi.org/10.1126/science.1231143

6. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096. https://doi.org/10.1126/science.1258096

7. Flugel, C. L., Cadinanos-Garai, A., & Abou-el-Enein, M. (2025). A clinical roadmap for base and prime editing. Nature Reviews Bioengineering, 3, 914–916. https://doi.org/10.1038/s44222-025-00360-z

8. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384, 252–260. https://doi.org/10.1056/NEJMoa2031054

9. Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature, 551, 464–471. https://doi.org/10.1038/nature24644

10. Gootenberg, J. S., Abudayyeh, O. O., Lee, J. W., Essletzbichler, P., Dy, A. J., Joung, J., et al. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356(6336), 438–442.

https://doi.org/10.1126/science.aam9321

11. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821.

https://doi.org/10.1126/science.1225829

12. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533, 420–424.

https://doi.org/10.1038/nature17946

ISBN: 978-93-49468-07-8

13. Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., et al. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823–826. https://doi.org/10.1126/science.1232033

14. Murray, J. B., Harrison, P. T., & Scholefield, J. (2025). Prime editing: Therapeutic advances and mechanistic insights. Gene Therapy, 32, 83–92. https://doi.org/10.1038/s41434-024-00499-1

15. Pacesa, M., Pelea, O., & Jinek, M. (2024). Past, present, and future of CRISPR genome editing technologies. Cell, 187(5), 1076–1100. https://doi.org/10.1016/j.cell.2024.01.042

16. Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152(5), 1173–1183. https://doi.org/10.1016/j.cell.2013.02.022

17. U.S. Food and Drug Administration. (2026). CASGEVY (exagamglogene autotemcel): Product information and approval history. https://www.fda.gov/vaccines-blood-biologics/casgevy

18. Villiger, L., Joung, J., Koblan, L., Weissman, J. S., Abudayyeh, O. O., &Gootenberg, J. S. (2024). CRISPR technologies for genome, epigenome and transcriptome editing. Nature Reviews Molecular Cell Biology, 25, 464–487. https://doi.org/10.1038/s41580-023-00697-6

19. World Health Organization. (2021). Human genome editing: Recommendations. World Health Organization.

https://www.who.int/publications/i/item/9789240030381.

☯☯☯

ISBN: 978-93-49468-07-8